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Background
Fibrosis is defined as an excessive accumulation of extra-
cellular matrix (ECM) components with an associated loss
of normal tissue architecture and function. Fibrosis occurs
in many different auto-inflammatory (auto-immune) dis-
eases. Current therapies targeting fibrosis are limited and
we are in great need for novel therapeutic regimens.
In fibrosis, abnormal fibroblast proliferation and ECM
production by fibroblasts is stimulated by factors released
by different cell types, amongst which macrophages.
Macrophages produce many pro-fibrotic factors, such as
IL-6, CCL2, PDGF and TGF-beta.
In rodent models of rheumatoid arthritis and inflam-
matory bowel disease, somatostatin analogues exerted
strong anti-inflammatory effects, by inhibition of pro-
inflammatory cytokine secretion. Somatostatin analogues
bind to somatostatin receptors (sst) and we demonstrated
sst subtype 2 expression on human macrophages.
In the present study we investigated the effects of
somatostatin, octreotide, a clinically used somatostatin
analogue, and cortistatin, an endogenously expressed
somatostatin-like peptide, on macrophage-induced fibro-
blast proliferation.
Materials and methods
A human fetal lung fibroblast cell line (HFL1) was used in
this study. Monocytes were isolated from healthy donors
and allowed to differentiate into macrophages. Fibroblasts
were co-cultured with macrophages or incubated with
conditioned macrophage media in the presence or absence
of lipopolysaccharide, somatostatin, octreotide or cortista-
tin. Thymidine incorporation was used to measure fibro-
blast proliferation.
Results
Culture of fibroblasts with media of unstimulated and LPS
stimulated macrophages resulted in an approximately
2-fold and 3-fold increase in proliferation, respectively.
Conditioned media from octreotide-treated LPS-acti-
vated macrophages showed a statistically lower activation
of fibroblast proliferation. In co-culture experiments
somatostatin, octreotide and cortistatin significantly inhib-
ited unstimulated macrophage-induced fibroblast prolif-
eration by approximately 30%, whereas these compounds
significantly inhibited LPS-stimulated macrophage-
induced fibroblast proliferation by 20%. As octreotide does
not bind to sst1 expressed on fibroblasts, at least the effects
of octreotide on fibroblast proliferation should be
mediated via macrophages.
Conclusions
In conclusion, macrophages significantly stimulate human
fetal lung fibroblast proliferation in vitro. Treatment of acti-
vated macrophages with somatostatin analogues signifi-
cantly decreased proliferation of fibroblasts. Ongoing
studies will reveal the cytokines and growth factors involved
in these actions, and whether their release by macrophages
is affected by somatostatin analogues. Based on these preli-
minary findings somatostatin analogues may be promising
agents in treatment of fibrotic diseases.
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